PHARMACEUTICAL COMPOSITION, INCLUDING A PH20 VARIANT OF HUMAN HYALURONIDASE, AND A MEDICINAL PRODUCT FOR SUBCUTANEOUS ADMINISTRATION Russian patent published in 2024 - IPC C12N9/26 C12N15/11 A61K47/42 A61K39/395 

Abstract RU 2810952 C2

FIELD: biotechnology.

SUBSTANCE: invention represents the use of PH20 variant containing one or more substitutions of amino acid residues selected from the group consisting of S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence SEQ ID NO: 1, to obtain a pharmaceutical composition that is thermostable for a long time, including: (a) a medicinal product; and (b) the said PH20 variant, and where the medicinal product is not pembrolizumab.

EFFECT: invention makes it possible to obtain thermostable compositions containing PH20 variant.

26 cl, 20 dwg, 12 tbl, 28 ex

Similar patents RU2810952C2

Title Year Author Number
NEW VERSIONS OF HYALURONIDASE WITH IMPROVED STABILITY AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM 2021
  • Park, Soon Jae
  • Chung, Hye-Shin
  • Lee, Seung Joo
  • Kim, Kyuwan
  • Song, Hyung-Nam
RU2811464C2
ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS 2012
  • Baurin, Nicolas
  • Beil, Christian
  • Corvey, Carsten
  • Lange, Christian
  • Li, Danxi
  • Mikol, Vincent
  • Steinmetz, Anke
  • Rao, Ercole
RU2823693C2
NEW VERSIONS OF HYALURONIDASE AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM 2019
  • Park, Soon Jae
  • Chung, Hye-Shin
  • Lee, Seung Joo
  • You, Sun-Ah
  • Song, Hyung-Nam
  • Lee, Chang Woo
RU2766680C1
VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN 2015
  • Shlotauer Tilman
RU2730592C2
VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A 2015
  • Shkolaut Aleksander
  • Shlotauer Tilman
RU2727639C2
METHOD OF PRODUCING A POLYPEPTIDE HETEROMULTITERS 2014
  • Igava Tomoyuki
  • Katada Khitosi
  • Mimoto Futa
RU2730594C2
PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 2019
  • Katagiri Takenobu
  • Tsukamoto Sho
  • Kumagai Keigo
  • Tsuji Shinnosuke
RU2783762C2
METHOD FOR PRODUCING A POLYPEPTIDE HETEROMULTIMER 2014
  • Igawa Tomoyuki
  • Katada Hitoshi
  • Mimoto Futa
RU2758952C1
ANTI-IL31 ANTIBODIES FOR VETERINARY USE 2018
  • Li, Shyr Jiann
  • Nguyen, Lam
  • Zhan, Hangjun
RU2795485C2
ANTIBODY TO TIGIT AND ITS USE 2019
  • Shi, Sinchzhen
  • Chzhan, Pan
  • Lyu, Tszyuntszyan
RU2786434C2

RU 2 810 952 C2

Authors

Park, Soon Jae

Chung, Hye-Shin

Lee, Seung Joo

Kim, Kyuwan

Byun, Minsoo

Nam, Ki Seok

Dates

2024-01-09Published

2020-03-24Filed